Ever wonder why our logo is a shield? Not only does it illustrate our three-step Purpose to #FindFightFollow disease, but it also represents #Lantheus’ threefold commitment, passion and desire to protect the health of everyone. From #prostatecancer to #CVD to #AlzheimersDisease, our team works tirelessly to deliver better patient outcomes. Learn more about what we do: https://www.lantheus.com
Lantheus
Pharmaceutical Manufacturing
Bedford, Massachusetts 20,746 followers
Find. Fight. Follow.™
About us
About us With more than 65 years of experience in delivering life-changing science, Lantheus is committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease. Lantheus is headquartered in Massachusetts and has offices in New Jersey, Canada and Sweden.
- Website
-
http://www.lantheus.com/
External link for Lantheus
- Industry
- Pharmaceutical Manufacturing
- Company size
- 501-1,000 employees
- Headquarters
- Bedford, Massachusetts
- Type
- Public Company
- Founded
- 1956
- Specialties
- Precision diagnostics, Targeted therapeutics, Radiopharmaceutical oncology, Artificial intelligence solutions, Strategic partnerships, and Just-in-time manufacturing
Locations
Employees at Lantheus
-
Cheryl Ball
Senior Vice President, Portfolio & Strategic Planning in Oncology
-
Leah Pfile, MBA
Marketing Leader | Executive Director
-
Jean-Claude Provost
Chief Medical Officer / Vice President / Research and Development in Pharmaceutical / Biotech / Life Sciences industry
-
Haresh Radadiya
Updates
-
We’re thrilled to introduce Neeron Sam, our Validation Engineer co-op, to Lantheus’ #CoOpCorner! Neeron, a Biotechnology major at Northeastern University, is juggling graduate courses with his bachelor’s degree and plans to complete both by the end of the summer term. At #Lantheus, Neeron is engaging deeply with Standard Operating Procedures (SOPs) essential for validation processes. He appreciates the supportive team environment and is keen to contribute to the validation team’s crucial work. Outside of work and academics, Neeron enjoys hiking, playing basketball and exploring diverse cuisines with his wife. We wish you a successful co-op experience at Lantheus, Neeron!
-
National #WomensEqualityDay, which commemorates the certification of the 19th Amendment more than 100 years ago, is a powerful reminder of the talent and influence of women and their integral voice in leadership since securing the right to vote. #Lantheus is proud to offer diverse professional opportunities and a platform for women to share their perspectives no matter where they are in their career journey, and our C-suite is no exception. To honor this day, we chatted with our Chief People Officer, Jamie Spaeth, to hear her reflections on women’s representation in companies and all facets of society. Read her thoughts below. ⬇️
-
#Lantheus is proud to have a robust team dedicated to our Purpose to #FindFightFollow disease for better patient outcomes. This year, we ranked #55 on the Boston Business Journal’s Largest Public Companies in Massachusetts list, and we’re looking for additional talent! We’re #hiring for a number of open positions across #TeamLantheus. Browse ➡️ https://bit.ly/LNTHCareers #LantheusIsHiring
-
We're grateful to see neuroendocrine tumors highlighted in the FY25 Senate Defense Appropriations Report. This support is vital for advancing research and improving outcomes for patients. #FindFightFollow
Neuroendocrine Tumors Included in FY25 Senate Defense Appropriations Report 🔗 https://bit.ly/4dlClDx “…to be used to conduct research in the following areas: bladder cancer; blood cancers; brain cancer; colorectal cancer; endometrial cancer; esophageal cancer; germ cell cancers; kidney cancer; liver cancer; lung cancer; lymphoma; mesothelioma; neuroblastoma; neuroendocrine tumors; pancreatic cancer; pediatric brain tumors; pediatric, adolescent, and young adult cancers; sarcoma; stomach cancer; and thyroid cancer.”
-
-
#NEWS: Lantheus today announced that Oliver Sartor, MD, Director of Radiopharmaceutical Trials and Professor of Medical Oncology at Mayo Clinic in Rochester, Minnesota, will deliver an oral presentation during the ESMO - European Society for Medical Oncology Congress on Sunday, September 15, 2024. Full release: https://bit.ly/3Mfhoyc #FindFightFollow #LeadingRadiopharma #prostatecancer
-
-
#TeamLantheus is proud to support the Alzheimer's Association® and participate in the #Walk2EndAlz this October. Join us to Find, Fight and Follow #AlzheimersDisease! ➡️ https://bit.ly/4g0fwHB #InOurHands #FingFightFollow #ENDALZ
We all have a reason to walk. Add your flower to the fight to #ENDALZ by registering for Walk to End Alzheimer’s at alz.org/Walk. Already participating? What color of flower will you carry? 💙 💜 💛 🧡 #Walk2EndAlz
-
Happy #NationalMassachusettsDay! We are committed to serving our local community through our work with initiatives and organizations like Rosie's Place, Boys & Girls Club of Greater Lowell, the Massachusetts chapter of the American Heart Association’s Boston Heart Walk, St. Jude Children's Research Hospital - ALSAC, ZERO Prostate Cancer’s Boston Run Walk, and the Alzheimer's Association®’s Walk to End Alzheimer’s. #TeamLantheus is proud to celebrate the state where we live and work to #FindFightFollow disease from our offices in Bedford and Billerica. Learn more about how we give back in MA: https://bit.ly/42hvTJ6 #OneLantheus
-
#ICYMI, last month our team was among the more than 14,000 life science professionals who attended the Alzheimer's Association®’s International Conference in Philadelphia. #TeamLantheus appreciated the opportunity to hear speakers Arnaud Charil, PhD and Keith Johnson, MD discuss recent advances in #AlzheimersDisease imaging biomarkers and meeting with other thought leaders to chat about our investigational next-generation PET radiodiagnostics. Shoutout to our Lantheus team in attendance! #AAIC24
-
#ICYMI: Lantheus President, Paul Blanchfield, joined the POLITICO stage in June, delving into the challenges related to patient access of #radiopharmaceutical diagnostics, providing “food for thought” to industry leaders in Washington, D.C. who can make a meaningful difference in policy and legislation. In July, #Lantheus welcomed the Centers for Medicare & Medicaid Services’s (CMS) Proposed Medicare Hospital Outpatient Prospective Payment System Rule for 2025, which offers improved access to radiopharmaceutical diagnostics to patients. Lantheus is proud to support this ruling and participate in events to raise awareness for bringing innovative solutions to patients with #prostatecancer, #Alzheimers, #cardiovasculardisease and other diseases. Watch the full video here: https://lnkd.in/ekJEiwhr #FindFightFollow #FINDAct #POLITICOHealth #GoFurther #LeadingRadiopharma